The expression of programmed cell death-ligand 1 (PD-L1) in tumour cells was significantly increased and tumour mutation burden tended to be increased after the development of resistance to EGFR-TKI treatment, which simultaneous affects the T cell receptor (TCR) clonality of tumour-infiltrating lymphocytes (TILs). This evidence concerns the gene EGFR and neoplasm.